1. Micali G, Gerber PA, Lacarrubba F, Schäfer G (2016) Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. J Clin Aesthet Dermatol 9(7):30–39
2. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F (2002) Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 46(4):584–587
3. Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M (2013) Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 12(6):650–656
4. Lacarrubba F, Verzì AE, Dinotta F, Scavo S, Micali G (2015) Dermatoscopy in inflammatory and infectious skin disorders. G Ital Dermatol Venereol 150(5):521–531
5. Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM (2015) Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 29(12):2405–2410